Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 220

1.

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis.

Nanni P, De Giovanni C, Burocchi A, Nicoletti G, Landuzzi L, Palladini A, Ianzano ML, Arioli I, Colombo MP, Lollini PL.

Oncoimmunology. 2018 Jun 11;7(8):e1465164. doi: 10.1080/2162402X.2018.1465164. eCollection 2018.

2.

A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors.

Leoni V, Vannini A, Gatta V, Rambaldi J, Sanapo M, Barboni C, Zaghini A, Nanni P, Lollini PL, Casiraghi C, Campadelli-Fiume G.

PLoS Pathog. 2018 Aug 6;14(8):e1007209. doi: 10.1371/journal.ppat.1007209. eCollection 2018 Aug.

3.

A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy.

Manara MC, Valente S, Cristalli C, Nicoletti G, Landuzzi L, Zwergel C, Mazzone R, Stazi G, Arimondo PB, Pasello M, Guerzoni C, Picci P, Nanni P, Lollini PL, Mai A, Scotlandi K.

Mol Cancer Ther. 2018 Sep;17(9):1881-1892. doi: 10.1158/1535-7163.MCT-17-0818. Epub 2018 Jun 29.

PMID:
29959201
4.

Cancer immunoprevention: from mice to early clinical trials.

Palladini A, Landuzzi L, Lollini PL, Nanni P.

BMC Immunol. 2018 Jun 15;19(1):16. doi: 10.1186/s12865-018-0253-0. Review.

5.

Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 is a Novel Post-Transcriptional Regulator of Ewing Sarcoma Malignancy.

Mancarella C, Pasello M, Ventura S, Grilli A, Calzolari L, Toracchio L, Lollini PL, Donati DM, Picci P, Ferrari S, Scotlandi K.

Clin Cancer Res. 2018 Aug 1;24(15):3704-3716. doi: 10.1158/1078-0432.CCR-17-2602. Epub 2018 Apr 27.

PMID:
29703820
6.

Virus-like antigen display for cancer vaccine development, what is the potential?

Sander AF, Lollini PL.

Expert Rev Vaccines. 2018 Apr;17(4):285-288. doi: 10.1080/14760584.2018.1455505. Epub 2018 Mar 30. No abstract available.

PMID:
29560746
7.

Virus-like particle display of HER2 induces potent anti-cancer responses.

Palladini A, Thrane S, Janitzek CM, Pihl J, Clemmensen SB, de Jongh WA, Clausen TM, Nicoletti G, Landuzzi L, Penichet ML, Balboni T, Ianzano ML, Giusti V, Theander TG, Nielsen MA, Salanti A, Lollini PL, Nanni P, Sander AF.

Oncoimmunology. 2018 Jan 5;7(3):e1408749. doi: 10.1080/2162402X.2017.1408749. eCollection 2018.

8.

Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1.

Palmerini E, Agostinelli C, Picci P, Pileri S, Marafioti T, Lollini PL, Scotlandi K, Longhi A, Benassi MS, Ferrari S.

Oncotarget. 2017 Dec 4;8(67):111836-111846. doi: 10.18632/oncotarget.22912. eCollection 2017 Dec 19.

9.

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response.

Palladini A, Nicoletti G, Lamolinara A, Dall'Ora M, Balboni T, Ianzano ML, Laranga R, Landuzzi L, Giusti V, Ceccarelli C, Santini D, Taffurelli M, Di Oto E, Asioli S, Amici A, Pupa SM, De Giovanni C, Tagliabue E, Iezzi M, Nanni P, Lollini PL.

Oncotarget. 2017 Apr 13;8(33):54444-54458. doi: 10.18632/oncotarget.17088. eCollection 2017 Aug 15.

10.

A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.

Gelfo V, Rodia MT, Pucci M, Dall'Ora M, Santi S, Solmi R, Roth L, Lindzen M, Bonafè M, Bertotti A, Caramelli E, Lollini PL, Trusolino L, Yarden Y, D'Uva G, Lauriola M.

Oncotarget. 2016 Nov 1;7(44):72167-72183. doi: 10.18632/oncotarget.12354.

11.

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.

Castagnoli L, Ghedini GC, Koschorke A, Triulzi T, Dugo M, Gasparini P, Casalini P, Palladini A, Iezzi M, Lamolinara A, Lollini PL, Nanni P, Chiodoni C, Tagliabue E, Pupa SM.

Oncogene. 2017 Mar 23;36(12):1721-1732. doi: 10.1038/onc.2016.338. Epub 2016 Sep 19.

12.

Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.

Leoni V, Gatta V, Palladini A, Nicoletti G, Ranieri D, Dall'Ora M, Grosso V, Rossi M, Alviano F, Bonsi L, Nanni P, Lollini PL, Campadelli-Fiume G.

Oncotarget. 2015 Oct 27;6(33):34774-87. doi: 10.18632/oncotarget.5793.

13.

The Promise of Preventive Cancer Vaccines.

Lollini PL, Cavallo F, Nanni P, Quaglino E.

Vaccines (Basel). 2015 Jun 17;3(2):467-89. doi: 10.3390/vaccines3020467. Review.

14.

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.

Croci S, Nanni P, Palladini A, Nicoletti G, Grosso V, Benegiamo G, Landuzzi L, Lamolinara A, Ianzano ML, Ranieri D, Dall'Ora M, Iezzi M, De Giovanni C, Lollini PL.

Breast Cancer Res. 2015 May 22;17:70. doi: 10.1186/s13058-015-0588-x.

15.

CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin.

Guerzoni C, Fiori V, Terracciano M, Manara MC, Moricoli D, Pasello M, Sciandra M, Nicoletti G, Gellini M, Dominici S, Chiodoni C, Fornasari PM, Lollini PL, Colombo MP, Picci P, Cianfriglia M, Magnani M, Scotlandi K.

Clin Cancer Res. 2015 Jan 1;21(1):146-56. doi: 10.1158/1078-0432.CCR-14-0492. Epub 2014 Dec 11.

16.

Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas.

Landuzzi L, Ianzano ML, Nicoletti G, Palladini A, Grosso V, Ranieri D, Dall'Ora M, Raschi E, Laranga R, Gambarotti M, Picci P, De Giovanni C, Nanni P, Lollini PL.

Oncotarget. 2014 Dec 15;5(23):11924-38.

17.

Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.

Castagnoli L, Iezzi M, Ghedini GC, Ciravolo V, Marzano G, Lamolinara A, Zappasodi R, Gasparini P, Campiglio M, Amici A, Chiodoni C, Palladini A, Lollini PL, Triulzi T, Menard S, Nanni P, Tagliabue E, Pupa SM.

Cancer Res. 2014 Nov 1;74(21):6248-59. doi: 10.1158/0008-5472.CAN-14-0983. Epub 2014 Aug 27.

18.

Multiple roles of perforin in hampering ERBB-2 (Her-2/neu) carcinogenesis in transgenic male mice.

Macagno M, Bandini S, Stramucci L, Quaglino E, Conti L, Balmas E, Smyth MJ, Lollini PL, Musiani P, Forni G, Iezzi M, Cavallo F.

J Immunol. 2014 Jun 1;192(11):5434-41. doi: 10.4049/jimmunol.1301248. Epub 2014 Apr 30.

19.

CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2.

Sciandra M, Marino MT, Manara MC, Guerzoni C, Grano M, Oranger A, Lucarelli E, Lollini PL, Dozza B, Pratelli L, Renzo MF, Colombo MP, Picci P, Scotlandi K.

J Bone Miner Res. 2014;29(5):1295-309. doi: 10.1002/jbmr.2141.

20.

An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas.

Guerzoni C, Amatori S, Giorgi L, Manara MC, Landuzzi L, Lollini PL, Tassoni A, Balducci M, Manfrini M, Pratelli L, Serra M, Picci P, Magnani M, Fusi V, Fanelli M, Scotlandi K.

BMC Cancer. 2014 Feb 27;14:137. doi: 10.1186/1471-2407-14-137.

21.

Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.

De Giovanni C, Nicoletti G, Quaglino E, Landuzzi L, Palladini A, Ianzano ML, Dall'Ora M, Grosso V, Ranieri D, Laranga R, Croci S, Amici A, Penichet ML, Iezzi M, Cavallo F, Nanni P, Lollini PL.

Breast Cancer Res. 2014 Jan 23;16(1):R10. doi: 10.1186/bcr3602.

22.

Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells.

Contaldo C, Myers TJ, Zucchini C, Manara MC, Chiodoni C, Colombo MP, Nicoletti G, Lollini PL, Li T, Longobardi L, Scotlandi K, Spagnoli A.

Growth Factors. 2014 Feb;32(1):41-52. doi: 10.3109/08977194.2013.870168. Epub 2014 Jan 20.

PMID:
24438070
23.

Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug.

Garofalo C, Capristo M, Manara MC, Mancarella C, Landuzzi L, Belfiore A, Lollini PL, Picci P, Scotlandi K.

PLoS One. 2013 Dec 31;8(12):e83832. doi: 10.1371/journal.pone.0083832. eCollection 2013.

24.

Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.

Ianzano ML, Croci S, Nicoletti G, Palladini A, Landuzzi L, Grosso V, Ranieri D, Dall'Ora M, Santeramo I, Urbini M, De Giovanni C, Lollini PL, Nanni P.

Oncotarget. 2014 Jan 15;5(1):108-19.

25.

Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells.

Calabrese C, Iommarini L, Kurelac I, Calvaruso MA, Capristo M, Lollini PL, Nanni P, Bergamini C, Nicoletti G, Giovanni CD, Ghelli A, Giorgio V, Caratozzolo MF, Marzano F, Manzari C, Betts CM, Carelli V, Ceccarelli C, Attimonelli M, Romeo G, Fato R, Rugolo M, Tullo A, Gasparre G, Porcelli AM.

Cancer Metab. 2013 Mar 18;1(1):11. doi: 10.1186/2049-3002-1-11.

26.

Preclinical vaccines against mammary carcinoma.

Lollini PL, Cavallo F, De Giovanni C, Nanni P.

Expert Rev Vaccines. 2013 Dec;12(12):1449-63. doi: 10.1586/14760584.2013.845530. Review.

27.

Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment.

Iommarini L, Kurelac I, Capristo M, Calvaruso MA, Giorgio V, Bergamini C, Ghelli A, Nanni P, De Giovanni C, Carelli V, Fato R, Lollini PL, Rugolo M, Gasparre G, Porcelli AM.

Hum Mol Genet. 2014 Mar 15;23(6):1453-66. doi: 10.1093/hmg/ddt533. Epub 2013 Oct 24.

PMID:
24163135
28.

Preclinical HER-2 Vaccines: From Rodent to Human HER-2.

Lollini PL, De Giovanni C, Nanni P.

Front Oncol. 2013 Jun 10;3:151. doi: 10.3389/fonc.2013.00151. eCollection 2013.

29.

CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity.

Zucchini C, Manara MC, Pinca RS, De Sanctis P, Guerzoni C, Sciandra M, Lollini PL, Cenacchi G, Picci P, Valvassori L, Scotlandi K.

Oncogene. 2014 Apr 10;33(15):1912-21. doi: 10.1038/onc.2013.152. Epub 2013 May 6.

PMID:
23644663
30.

Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.

Nanni P, Gatta V, Menotti L, De Giovanni C, Ianzano M, Palladini A, Grosso V, Dall'ora M, Croci S, Nicoletti G, Landuzzi L, Iezzi M, Campadelli-Fiume G, Lollini PL.

PLoS Pathog. 2013 Jan;9(1):e1003155. doi: 10.1371/journal.ppat.1003155. Epub 2013 Jan 31.

31.

Human responses against HER-2-positive cancer cells in human immune system-engrafted mice.

De Giovanni C, Nicoletti G, Landuzzi L, Romani F, Croci S, Palladini A, Murgo A, Antognoli A, Ianzano ML, Stivani V, Grosso V, Iezzi M, Stramucci L, Barbieri E, Lemoli RM, Nanni P, Lollini PL.

Br J Cancer. 2012 Oct 9;107(8):1302-9. doi: 10.1038/bjc.2012.394. Epub 2012 Aug 28.

32.

DNA vaccination against oncoantigens: A promise.

Iezzi M, Quaglino E, Amici A, Lollini PL, Forni G, Cavallo F.

Oncoimmunology. 2012 May 1;1(3):316-325.

33.

Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor.

Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano ML, Grosso V, Stivani V, Antognoli A, Lamolinara A, Landuzzi L, di Tomaso E, Iezzi M, De Giovanni C, Lollini PL.

PLoS One. 2012;7(6):e39626. doi: 10.1371/journal.pone.0039626. Epub 2012 Jun 21.

34.

Oncoantigens for an immune prevention of cancer.

Bolli E, Quaglino E, Arigoni M, Lollini PL, Calogero R, Forni G, Cavallo F.

Am J Cancer Res. 2011;1(2):255-264. Epub 2010 Dec 20.

35.

A mutation threshold distinguishes the antitumorigenic effects of the mitochondrial gene MTND1, an oncojanus function.

Gasparre G, Kurelac I, Capristo M, Iommarini L, Ghelli A, Ceccarelli C, Nicoletti G, Nanni P, De Giovanni C, Scotlandi K, Betts CM, Carelli V, Lollini PL, Romeo G, Rugolo M, Porcelli AM.

Cancer Res. 2011 Oct 1;71(19):6220-9. doi: 10.1158/0008-5472.CAN-11-1042. Epub 2011 Aug 18.

36.

The molecular basis of herpesviruses as oncolytic agents.

Menotti L, Campadelli-Fiume G, Nanni P, Lollini PL, De Giovanni C.

Curr Pharm Biotechnol. 2012 Jul;13(9):1795-803. Review.

PMID:
21740356
37.

Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy.

Pasello M, Manara MC, Michelacci F, Fanelli M, Hattinger CM, Nicoletti G, Landuzzi L, Lollini PL, Caccuri A, Picci P, Scotlandi K, Serra M.

Anal Cell Pathol (Amst). 2011;34(3):131-45. doi: 10.3233/ACP-2011-012.

38.

Rethinking herpes simplex virus: the way to oncolytic agents.

Campadelli-Fiume G, De Giovanni C, Gatta V, Nanni P, Lollini PL, Menotti L.

Rev Med Virol. 2011 Jul;21(4):213-26. doi: 10.1002/rmv.691. Epub 2011 May 27. Review.

PMID:
21626603
39.

HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines.

Landuzzi L, Antognoli A, Nicoletti G, Croci S, Palladini A, Ianzano ML, Murgo A, Stivani V, Grosso V, Nanni P, De Giovanni C, Lollini PL.

Vaccine. 2011 Jun 24;29(29-30):4690-7. doi: 10.1016/j.vaccine.2011.04.096. Epub 2011 May 11.

PMID:
21569812
40.

Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.

Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, Pandini G, López-Guerrero JA, Schaefer KL, Belfiore A, Picci P, Scotlandi K.

Oncogene. 2011 Jun 16;30(24):2730-40. doi: 10.1038/onc.2010.640. Epub 2011 Jan 31.

PMID:
21278796
41.

2011: the immune hallmarks of cancer.

Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL.

Cancer Immunol Immunother. 2011 Mar;60(3):319-26. doi: 10.1007/s00262-010-0968-0. Epub 2011 Jan 26.

42.

Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.

Pantaleo MA, Nicoletti G, Nanni C, Gnocchi C, Landuzzi L, Quarta C, Boschi S, Nannini M, Di Battista M, Castellucci P, Fanti S, Lollini PL, Bellan E, Castelli M, Rubello D, Biasco G.

J Exp Clin Cancer Res. 2010 Dec 30;29:173. doi: 10.1186/1756-9966-29-173.

43.

Vaccines and other immunological approaches for cancer immunoprevention.

Lollini PL, Nicoletti G, Landuzzi L, Cavallo F, Forni G, De Giovanni C, Nanni P.

Curr Drug Targets. 2011 Dec;12(13):1957-73. Review.

PMID:
21158706
44.

Modeling the competition between lung metastases and the immune system using agents.

Pennisi M, Pappalardo F, Palladini A, Nicoletti G, Nanni P, Lollini PL, Motta S.

BMC Bioinformatics. 2010 Oct 15;11 Suppl 7:S13. doi: 10.1186/1471-2105-11-S7-S13.

45.

TRAF6 regulates proliferation and differentiation of skeletal myoblasts.

Mueck T, Berger F, Buechsler I, Valchanova RS, Landuzzi L, Lollini PL, Klingel K, Munz B.

Differentiation. 2011 Feb;81(2):99-106. doi: 10.1016/j.diff.2010.11.002. Epub 2010 Dec 4.

PMID:
21131124
46.

Immunoprevention and immunotherapy of mammary carcinoma.

Lollini PL, Nicoletti G, Landuzzi L, De Giovanni C, Nanni P.

Breast J. 2010 Sep-Oct;16 Suppl 1:S39-41. doi: 10.1111/j.1524-4741.2010.01002.x.

PMID:
21050308
47.

Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system.

Croci S, Recktenwald CV, Lichtenfels R, Nicoletti G, Dressler SP, De Giovanni C, Astolfi A, Palladini A, Shin-ya K, Landuzzi L, Nanni P, Lollini PL, Seliger B.

Proteomics. 2010 Nov;10(21):3835-53. doi: 10.1002/pmic.200900643.

PMID:
20957756
48.

In silico modeling and in vivo efficacy of cancer-preventive vaccinations.

Palladini A, Nicoletti G, Pappalardo F, Murgo A, Grosso V, Stivani V, Ianzano ML, Antognoli A, Croci S, Landuzzi L, De Giovanni C, Nanni P, Motta S, Lollini PL.

Cancer Res. 2010 Oct 15;70(20):7755-63. doi: 10.1158/0008-5472.CAN-10-0701. Epub 2010 Oct 5.

49.

ImmunoGrid: towards agent-based simulations of the human immune system at a natural scale.

Halling-Brown M, Pappalardo F, Rapin N, Zhang P, Alemani D, Emerson A, Castiglione F, Duroux P, Pennisi M, Miotto O, Churchill D, Rossi E, Moss DS, Sansom CE, Bernaschi M, Lefranc MP, Brunak S, Lund O, Motta S, Lollini PL, Murgo A, Palladini A, Basford KE, Brusic V, Shepherd AJ.

Philos Trans A Math Phys Eng Sci. 2010 Jun 13;368(1920):2799-815. doi: 10.1098/rsta.2010.0067.

50.

Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.

Pantaleo MA, Mishani E, Nanni C, Landuzzi L, Boschi S, Nicoletti G, Dissoki S, Paterini P, Piccaluga PP, Lodi F, Lollini PL, Fanti S, Biasco G.

Mol Imaging Biol. 2010 Dec;12(6):616-25. doi: 10.1007/s11307-010-0315-z.

Supplemental Content

Loading ...
Support Center